Wasson Walgreen CEO
This article was originally published in The Tan Sheet
Executive Summary
The drugstore chain promotes 29-year company veteran Gregory D. Wasson to CEO and a director effective Feb. 1. Wasson started out as a Walgreen pharmacy intern in 1980, eventually becoming president and chief operating officer in 2007, the Deerfield, Ill.-based company says Jan. 26. The CEO search committee praises Wasson's "breadth and depth of industry experience" in consumer marketing and retail operations. The new head will preside over a period in which Walgreens pledged to refocus on its core businesses and cut $1 billion from capital spending in the next three years. Former CEO Jeffrey A. Rein left the company in October 2008 after Walgreens' bid to acquire Longs Drug Stores failed (1"The Tan Sheet" Oct. 13, 2008, In Brief)
You may also be interested in...
Walgreens drops Longs bid
Walgreens withdraws its proposed purchase of all outstanding shares of Longs Drug Stores Corp. in light of the Longs' board's decision to accept the tender offer made by CVS/Caremark, Walgreens CEO Jeffrey A. Rein says in an Oct. 8 letter. Walgreens' offer of $75 per share was rejected by Longs in September (1"The Tan Sheet" Sept 22, 2008, In Brief). Rein announced Oct. 10 he was leaving after 26 years with the company, effective immediately. The Deerfield, Ill.-based company named Alan G. McNally, lead director of its board, as chairman and acting CEO
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.